

TO BE
LAUNCHED!

IDYLLA™ PIK3CA-AKT1 MUTATION ASSAY

For the molecular characterization
of Hormone Receptor positive (HR+)
HER2 negative (HER2-) metastatic
breast cancer



THINK IDYLLA™
BECAUSE TIME MATTERS

Idylla™ Platform is CE-marked IVD in Europe. Idylla™ PIK3CA-AKT1 Mutation Assay is currently under development and will be released for Research Use Only (RUO), not for use in diagnostic procedures. ©Biocartis, August 2022

TO BE LAUNCHED!

IDYLLA™ PIK3CA-AKT1 MUTATION ASSAY (RUO)

FOR THE MOLECULAR CHARACTERIZATION OF HORMONE
RECEPTOR POSITIVE (HR+) HER2 NEGATIVE (HER2-)
METASTATIC BREAST CANCER



Qualitative detection of 13 **PIK3CA** mutations
and one **AKT1** mutation **in a single cartridge**



Assay running on fully automated molecular testing platform
No sample batching required



Less than 2 minutes hands-on time
Assay turnaround time < 150 minutes



Directly from FFPE tissue

Biocartis NV
Generaal de Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888

www.biocartis.com
customerservice@biocartis.com

Follow us on   



THINK IDYLLA™
BECAUSE TIME MATTERS

Idylla™ Platform is CE-marked IVD in Europe. Idylla™ PIK3CA-AKT1 Mutation Assay is currently under development and will be released for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ is available for sale in EU, USA and many other countries. Please check availability with the local Biocartis representative. Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis. © Biocartis NV, August 2022.